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Interventions that can block the transmission of malaria-causing Plasmodium falciparum (Pf)
between the human host and Anopheles vector have the potential to reduce the incidence of
malaria. Pfs48/45 is a gametocyte surface protein critical for parasite development and
transmission, and its targeting by monoclonal antibody (mAb) 85RF45.1 leads to the potent
reduction of parasite transmission. Here, we reveal how the Pfs48/45 6C domain adopts a
(SAG1)-related-sequence (SRS) fold. We structurally delineate potent epitope I and show
how mAb 85RF45.1 recognizes an electronegative surface with nanomolar afﬁnity. Analysis
of Pfs48/45 sequences reveals that polymorphisms are rare for residues involved at the
binding interface. Humanization of rat-derived mAb 85RF45.1 conserved the mode of
recognition and activity of the parental antibody, while also improving its thermostability. Our
work has implications for the development of transmission-blocking interventions, both
through improving vaccine designs and the testing of passive delivery of mAbs in humans.
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Malaria is a global health priority, with an estimated 216million cases worldwide in 2016 alone1. The Plasmo-dium falciparum (Pf) parasite is responsible for most
malaria-related mortalities, with over two-thirds occurring in
children under 5 years of age. Disrupting the Pf life cycle as the
parasite circulates between humans and Anopheles mosquitoes
has the potential to reduce infections within communities, and
thus reduce illness and death2. It was recognized decades ago that
antibodies have the potential to inhibit onward transmission of
the parasite when passed by malaria-infected humans to the
Anopheles mosquito vector3–5. Transmission-blocking vaccines
(TBVs) are based on this principle, and aim to elicit antibodies in
humans that can reduce Pf transmission to the vector when
mosquitoes ingest these antibodies during feeding6. Target pro-
teins for TBV development are located on the surface of game-
tocytes/gametes (P48/457, P2308) and zygotes/ookinetes (P25,
P28)9,10, or are expressed within the mosquito midgut (e.g.
APN111 and FREP112).
Pfs48/45 is a cysteine-rich surface protein that plays a critical
role in male gamete fertility13. Antibodies against Pfs48/45 have
been shown to prevent parasite development and
transmission14,15. Because Pfs48/45 is located on gametocytes/
gametes that circulate in humans, naturally occurring antibodies
against Pfs48/45 can be elicited in individuals living in malaria-
endemic areas, and these antibodies have been demonstrated to
possess transmission-blocking activity16–21.
Pfs48/45 is organized into three domains, and epitope mapping
has identiﬁed at least ﬁve predominant sites of antibody recog-
nition that span its primary sequence22,23 (Fig. 1a). Human,
murine, and rat monoclonal antibodies (mAbs) have been derived
that target epitopes I, IIb, III, and V5,24–26. Of these, mAb
85RF45.1, derived from rats immunized with whole gametocytes
followed by fusion and screening by enzyme-linked immuno-
sorbent assay for Pfs48/45 antibodies, was shown to be the most
potent at inhibiting parasite transmission to Anopheles mosqui-
toes24. mAb 85RF45.1 is a rat IgG1 that binds to epitope I on
Pfs48/4524.
A three-dimensional structure of Pfs48/45 remains elusive.
Such information would provide useful in devising strategies for
improved recombinant expression of immunogens; indeed,
monodisperse Pfs48/45 has been challenging to obtain and
development of homogeneous and stable recombinant constructs
is an area of intense research7,25,27–30. A molecular understanding
of mAb 85RF45.1 binding to Pfs48/45 would also provide the
blueprints for the development of next-generation Pfs48/45
immunogens that optimally present this potent epitope to be
tested as TBVs. In addition, molecular details of this
antibody–antigen interaction could facilitate the development of
new antibody interventions. Here, we present the three-
dimensional structure of the Pfs48/45 6C domain and delineate
the potent 85RF45.1 epitope structurally. We also provide
molecular details for the development of mAb TB31F, a huma-
nized version of rat mAb 85RF45.1 with improved biophysical
properties, now undergoing preclinical development.
Results
mAb 85RF45.1 recognizes a conformational epitope on Pfs48/
45. To uncover the potent epitope on Pfs48/45 bound by
transmission-blocking mAb 85RF45.1, we solved the co-crystal
structure of the 85RF45.1 Fab-Pfs48/45 6C complex to 2.7 Å
resolution (Fig. 1b and Supplementary Table 1). All six com-
plementarity determining regions (CDRs) are involved in med-
iating interactions with a conformational epitope on Pfs48/45
(Fig. 1c). The buried surface area of mAb 85RF45.1 on its antigen
is extensive (1039 Å2), and primarily contributed by the heavy
chain (650 Å2), and less by the light chain (389 Å2) (Supple-
mentary Table 2). Ten discontinuous residues on Pfs48/45 are
contacted by the antibody to form salt bridges or H-bonds,
namely G346, D347, D351, Q355, E365, K394, K413, K414, D415,
and K416 (Fig. 1c, insets). Our structural delineation of the
antibody–antigen complex corroborates the importance of dis-
ulﬁde bonds and protein conformation for epitope I established
by previous biochemical characterization24.
The Pfs48/45 6C domain adopts a SRS fold. Analysis of the
Pfs48/45 6C sequence reveals that proteins with the highest
sequence identity include Pfs48/45 orthologs from Plasmodium
vivax, malariae, and ovale (62–64%), as well as the gamete surface
protein Pfs47 (27%) (Fig. 2a). Our crystal structure of Pfs48/45
6C now also allows for a complete analysis of its homology.
Pfs48/45 6C contains a mix of parallel and anti-parallel ß-strands
that organize in a ﬁve-on-four ß sandwich (a, a′, c, e, and f on b,
d, g, and h), which is consistent with the (SAG1)-related-
sequence (SRS) fold. The six cysteines in Pfs48/45 6C are paired
in a C1–C2, C3–C6, C4–C5 disposition: C298–C327, C344–C412,
and C352–C410 (Figs. 1a and 2b), as consistent with previous
biochemical analysis of tryptic peptides by LC–MS/MS30. These
disulﬁde bonds connect strands a and b, strands c and g, and loop
d–d′ to strand g, respectively (Fig. 2b). The three proteins of
known structure with highest structural similarity with Pfs48/45
6C are schizont surface protein Pf12 (Z-score 12.9), merozoite
surface protein Pf41 (Z-score 12.0), and Toxoplasma gondii
sporozoite-speciﬁc SAG protein (Z-score 10.5) (Fig. 2c)31. Pfs48/
45 6C only shares 16–22% sequence identify with these proteins
and consequently displays unique surface properties likely
involved in male gamete fertility and giving the protein its distinct
immunogenicity (Supplementary Figure 1).
N-linked glycosylation improves expression of Pfs48/45 6C.
The Pfs48/45 6C construct used for structure determination
was expressed in HEK293 mammalian cells, thus in a system
capable of post-translational modiﬁcations. The primary amino
acid sequence of Pfs48/45 6C encodes for two putative N-linked
glycosylation sites when expressed in mammalian cells: N299
(NFS) and N303 (NVS), both located near the N terminus of
the construct. Our crystal structure revealed that N303 is
indeed glycosylated, and harbors a NAG residue residual from
Endoglycosidase H (Endo H) treatment (Fig. 3a). In fact,
NAG303 forms H-bonds with D390 and D391 of the neigh-
boring loop and buries approximately 150 Å2 of surface area on
the two loops that connect strands a–a′ and strands e–f
(Fig. 3a). On the other hand, N299, which immediately follows
C298, is not glycosylated, and instead its sidechain plays an
important structural role in the strand a-loop-strand a′ motif,
mediating H-bonds with S301 (Fig. 3a). To determine whether
N-linked glycosylation played a role in the expression of Pfs48/
45 6C in our HEK293 system, we created single and double
mutants removing the N-linked glycosylation sequon by
introducing S301A and S305A mutations. Expression tests
showed a substantial decrease in recovered protein levels when
removing N303 glycosylation, with the double mutant yielding
almost no Pfs48/45 6C (Fig. 3b). N-linked glycosylation was
also critical to obtain a monomeric and monodisperse Pfs48/45
6C sample, as observed by size-exclusion chromatography
(Fig. 3c). Importantly, the N303 N-linked glycan is distally
located from the 85RF45.1 epitope. N-linked glycosylation
resulting from expression in mammalian cells therefore favors
production of well-folded Pfs48/45 6C, without affecting
exposure of potent epitope I.
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The 85RF45.1 epitope contains few sequence polymorphisms.
Next, we structurally mapped the sequence diversity documented
for Pfs48/45. Deposited sequences of the Pfs48/45 6C domain
from UniProt (28), NCBI (61), and PlasmoDB (195) revealed the
following polymorphisms: V/D304, S/G313, L/I314, D/G315, S/
N/C322, E/G333, I/V349, Q/L355, V/A356, A/T387, K/R404, K/
E414, and T/I422 (Fig. 4a). The ﬁve Pfs48/45 residues pre-
dominantly involved in interacting with 85RF45.1 (D347, D351,
K413, D415, and K416; all mediating extensive H-bonds/salt
bridges and with individual BSA > 75 Å2) are invariant (Fig. 4a).
Two other Pfs48/45 residues mediating H-bonds with 85RF45.1
(E365 and K394) are also invariant (Fig. 4a). Nonetheless, three
Pfs48/45 residues that are contacted by 85RF45.1 have docu-
mented polymorphisms (Fig. 4b): 349 is almost always Ile, but
one sequence is reported with a Val at that position (AAL74379.1
[https://www.ncbi.nlm.nih.gov/protein/AAL74379.1])32; 355 is
almost always Gln, but one sequence is reported with a Leu at that
position (AAL74377.1 [https://www.ncbi.nlm.nih.gov/protein/
AAL74377.1])32; 414 is almost always Lys, but one sequence is
reported with a Glu at that position (AAL74361.1 [https://www.
ncbi.nlm.nih.gov/protein/AAL74361.1])32. 85RF45.1 buries 36,
46, and 20 Å2 of surface area on these three residues, respectively.
Binding measurements of 85RF45.1 Fab to Pfs48/45 6C con-
structs possessing single point mutations that represent these
polymorphisms revealed that the antibody is still capable of
binding its epitope with nanomolar afﬁnity (Fig. 4c). We con-
clude that the 85RF45.1 epitope is predominantly conserved, with
rare polymorphisms located in secondary epitope regions (indi-
vidual residues each represent <5% of total buried surface area).
Humanization of mAb 85RF45.1. Next, we sought to humanize
mAb 85RF45.1, introducing as much human sequence as possible
while retaining sequences that preserve the binding characteristics
of the antibody. The closest human V germlines to the parental
rat sequence were found to be IGLV6–57 (66.2% for the light
chain) and IGHV3–7 (84.0% for the heavy chain). Three huma-
nized light chains and three humanized heavy chains were
designed, all exceeding our threshold humanness scores (Sup-
plementary Figure 2). In all cases, CDRs remained unchanged.
Three humanized light and heavy chains were combined to create
a total of nine fully-humanized variant antibodies (Supplemen-
tary Figure 2). All three light chain combinations within the HC2
group bound the antigen similarly and the HC2 group afﬁnities
were higher than the HC1 and HC3 groups (Supplementary
Figure 2). The HC2-LC1 (hereafter named TB31F, Fig. 5a) was
selected for further characterization based on high binding
activity and high human-like scores.
To characterize the ability of mAb TB31F to recognize Pfs48/
45, we solved the crystal structure of TB31F Fab in complex with
Pfs48/45 6C to 2.6 Å resolution (Fig. 5b and Supplementary
Table 1). As expected from the preservation of CDR residues
during humanization, mAb TB31F forms similar contacts with
Pfs48/45 6C as mAb 85RF45.1 (Fig. 5b and Supplementary
Table 2), with slight differences primarily attributable to ﬂexible
loops in Pfs48/45 6C and crystal packing contacts. Next, we
investigated whether amino acid changes in the antibody
framework regions during humanization impacted the structural
disposition of CDRs. Crystal structures of unliganded 85RF45.1
Fab and unliganded TB31F Fab, solved to 3.15 and 1.5 Å
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resolutions, respectively, revealed a strikingly similar paratope
conﬁguration (Fig. 5c). The all-atom rmsd between the two
unliganded variable domains is 0.88 Å, primarily arising from
differences in loop conformations within the framework regions
(Fig. 5c). These structures also revealed how the variable region is
optimally conﬁgured for binding Pfs48/45 even when unliganded
(all-atom rmsd 85RF45.1bound/unbound: 1.52 Å; TB31Fbound/unbound:
1.25 Å). Despite this high structural similarity, amino acid
changes during humanization resulted in electrostatic surfaces
that are considerably different between the 85RF45.1 and TB31F
variable regions, indicating the attainment of antibody resurfa-
cing (Fig. 5d). Importantly, both 85RF45.1 Fab and TB31F Fab
bound the antigen with nanomolar binding afﬁnities (Fig. 5e and
Supplementary Figure 3A) and the two mAbs inhibited 80% of
oocyst intensity at similar concentrations of approximately 1 µg/
mL (Fig. 5e, Supplementary Figure 4 and Supplementary Table 3).
TB31F Fab also retained the ability of 85RF45.1 Fab to recognize
Pfs48/45 with sequence polymorphisms in its epitope (Supple-
mentary Figure 3B). In unfolding and aggregation experiments,
TB31F Fab was found to have gained in thermostability, with a
melting temperature (Tm) of 74.8 °C and an aggregation
temperature (Tagg) of 73.0 °C, compared to 63.1 and 63.8 °C for
85RF45.1 Fab, respectively (Fig. 5e and Supplementary Figures 5
and 6). TB31F Fab shows thermostability throughout a wide pH
range, whereas 85RF45.1 Fab is more dependent on pH
(Supplementary Figures 5 and 6). These desirable biophysical
properties for TB31F, combined with its retained nanomolar
binding afﬁnity and potent activity to inhibit parasite transmis-
sion, make this molecule an attractive biologic for malaria
interventions.
Discussion
Pfs48/45 is a prominent target for the development of biomedical
interventions that can interrupt the transmission of Pf and con-
tribute to the decrease of malaria incidence. Here, we report the
three-dimensional structure of the Pfs48/45 6C domain and
delineate the epitope targeted by one of the most potent
transmission-blocking mAbs yet described, 85RF45.1.
Pfs48/45 6C adopts an SRS fold that consists of two β-sheets
formed by a mix of parallel and anti-parallel β-strands. This fold
has been proposed to derive from an ephrin-like precursor during
evolution and is predicted to be adopted by at least 14 proteins in
Pf33,34. Correspondingly, proteins of known structures that have
the highest structural homology are parasitic proteins of this s48/
45 family for which structures have been determined: Pf12 (Pf),
Pf41 (Pf), and Sporosag (Toxoplasma gondii). It is thought that
these glycosylphosphatidylinositol (GPI)-anchored parasitic pro-
teins play an important role in cell adhesion and immune evasion,
although no exact function has yet been assigned to Pf12 and
Pf4134. Our structure also reveals that the electrostatic surface of
Pfs48/45 6C is highly electronegative. Whether this property is
associated with its function in male gamete fertility13 and
involved in ligand binding or scaffolding in a multi-protein
complex35 will be an important area of further studies. It will also
be important to determine whether the potency of mAb 85RF45.1
is associated with disruption of the Pfs48/45 epitope I in
protein–protein interactions.
To obtain the crystal structure of the 85RF45.1 Fab-Pfs48/45
6C complex, we expressed the antigen in mammalian cells, thus
allowing for extensive post-translational modiﬁcations. The
ability of Pf to carry out post-translational modiﬁcations and
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their exact composition is an area of active investigation36–38, but
it remains largely unclear how frequent N-linked glycosylation is
on Pf surface proteins in the presence of NXS/T sequons39. Here,
we found N-linked glycosylation to be critical for monodisperse
Pfs48/45 6C expression. Accordingly, we observed in our Pfs48/
45 6C crystal structures that a NAG residue at position 303 can
bury >150 Å2 of surface area between two loops and mediates
H-bonds with Pfs48/45 residues. Interestingly, in homologous
merozoite protein Pf41, the location of the NAG residue in our
Pfs48/45 6C structure is occupied by a helix from an upstream
Pf41 N-terminal domain, which stacks against a similar groove. It
is thus possible that in full-length Pfs48/45 elements located N-
terminal of the Pfs48/45 6C fragment help stabilize the structure
in a similar fashion. This hypothesis would be in agreement with
the observation that refolding capacity was superior for a con-
struct comprising both the middle four-cysteine domain and the
C-terminal six-cysteine domain (10C)15. The success of fusing the
N terminus of Pf glutamate-rich protein (PfGLURP R0 fragment)
to express Pfs48/45 6C (R0.6C)30 might also emanate from such
favorable inter-domain stabilizing effects, possibly at the site
occupied by the NAG residue here. Thus, our three-dimensional
structures of Pfs48/45 6C now provide an opportunity for protein
engineering to further stabilize the antigen, enhance its expres-
sion, and develop TBV immunogens that will optimally present
epitope I to preferentially elicit potent transmission-blocking
antibodies.
mAb 85RF45.1 is one of the most potent antibodies identiﬁed
against any transmission-blocking target, with an IC80 of
approximately 1–3 μg/mL in standard membrane feeding assay
(SMFA) experiments. We also now reveal that its epitope is lar-
gely conserved: mAb 85RF45.1 can accommodate all sequence
polymorphisms previously reported and still bind with nano-
molar afﬁnity. However, whether this antibody can block ﬁeld
isolates containing these polymorphisms remains to be deter-
mined. mAb 85RF45.1 represents a unique tool to assess the
efﬁcacy of antibodies to reduce Pf transmission and malaria
incidence in affected communities. For this purpose, optimizing
the developability of this rat-originating mAb was an important
objective. Here, we show how humanization of mAb 85RF45.1
into mAb TB31F retained the exact molecular mode of recogni-
tion of Pfs48/45, its high-afﬁnity binding to the antigen, and its
potent transmission-reducing activity in SMFA. In addition,
humanized TB31F Fab shows improved thermostability char-
acteristics with ~10 °C higher Tm and Tagg compared to its rat-
derived counterpart. Thus, our data provide a salient example of
how humanization can present an opportunity to simultaneously
improve surface and biophysical proﬁles of non-human-derived
mAbs, and will contribute to ongoing efforts to improve multi-
objective antibody optimization functions40,41.
mAb TB31F now offers a unique opportunity to test the efﬁ-
cacy of a Pfs48/45-based transmission-blocking intervention in
humans. The mAb has entered good manufacturing production
and preclinical safety testing. Phase I trials are planned to assess
safety and tolerability. Pending a positive outcome, this will be
followed by efﬁcacy testing with the goal of establishing the level
of mAb required to block parasite transmission from human to
mosquito, as determined by direct skin feeding (infection pre-
valence endpoint). Comparison of these data to those from the
laboratory-based SMFA, which employs an infection intensity (as
opposed to infection prevalence) endpoint and is routinely used
to inform go/no-go criteria in pre- and early-clinical testing, will
enable “back-validation” of the SMFA to better inform its use as
an early development stage-gate for measuring the efﬁcacy of
candidate vaccines and antibodies. Such results will also provide a
benchmark for performance of future vaccines and validate the
epitope studied here as an important target.
Methods
Cloning of the 85RF45.1 antibody from hybridoma. Sequencing and cloning of
the rat hybridoma immunoglobulin genes were performed by LakePharma, Inc.,
Belmont, CA. Sequencing included cDNA synthesis, PCR with rat heavy and light
chain primers, subcloning of correct-sized bands into TOPO vectors, and DNA
sequencing of individual ampliﬁed clones. Native 85RF45.1 and chimeric 85RF45.1
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(fused to human IgG1 constant regions) antibodies were cloned into LakePharma’s
high expression mammalian vector system and transient production was per-
formed in HEK293 cells (Thermo Fisher Scientiﬁc). Starting at 20 h, and
throughout the transient transfection production, antibody titers were measured
(Octet QKe, ForteBio). Cultures were harvested at day 5 and antibodies in the
conditioned media were puriﬁed using MabSelect SuRe Protein A resin (GE
Healthcare) for validation.
Humanization of mAb 85RF45.1. Humanized antibodies were designed by creating
multiple hybrid sequences that fuse select parts of the parental antibody sequence with
the human framework sequences. Humanness scores, representing how human-like
the antibody variable region sequence is, were calculated according to Gao et al.42.
Based on the method employed, heavy chain scores of 79 or above were considered
human-like; for lambda light chains, a score of 84 or above was considered human-
like. Full-length antibody genes for all nine heavy/light chain pairs were constructed
by cloning the synthesized variable region sequences into expression vectors that
contained the human IgG1 or lambda constant region genes.
Expression and puriﬁcation of Fabs and antigens. The VL and VH regions of
mAb TB31F and mAb 85RF45.1 were cloned into the pHLsec expression vector43
upstream of human Igλ and CH1 constant regions, respectively. Fabs were expressed
in HEK293F cells (Thermo Fisher Scientiﬁc) and puriﬁed by afﬁnity chromatography
using a HiTrap LambdaSelect column (GE Healthcare), followed by ion exchange
(MonoS; GE Healthcare) and gel ﬁltration (Superdex 200 Increase 10/300 GL; GE
Healthcare) chromatography. The NF54 [https://www.ncbi.nlm.nih.gov/protein/
AHA91190.1] Pfs48/45 6C gene was codon-optimized for expression in mammalian
cells, was cloned in the pHLsec expression vector43, and was puriﬁed by afﬁnity
chromatography (HisTrapFF; GE Healthcare) followed by gel ﬁltration chromato-
graphy (Superdex 200 Increase 10/300 GL; GE Healthcare). The R0.6C protein was
produced as previously described30.
Complex formation of Pfs48/45 6C with 85RF45.1 and TB31F Fabs. To obtain
high yields of antigen–antibody complexes, plasmids for the TB31F and 85RF45.1
Fab heavy and light chains were mixed with the Pfs48/45 6C plasmid in a ratio of
60:30:40 and transfected in HEK293S cells (GnT I−/−) (ATCC CRL-3022).
85RF45.1 Fab-Pfs48/45 6C and TB31F Fab-Pfs48/45 6C complexes were puriﬁed
by afﬁnity chromatography (HisTrapFF; GE Healthcare), treated with Endo H, and
puriﬁed by cation exchange chromatography (MonoS; GE Healthcare).
Crystallization and structure determination. Hanging or sitting drop crystal-
lization trials were set up using commercial sparse-matrix screens (Rigaku TOP96
and Anatrace MCSG 1) and hits were subsequently reﬁned. 85RF45.1 and TB31F
Fabs were set up at 8 mg/mL, while 85RF45.1 Fab-Pfs48/45 6C and TB31F Fab-
Pfs48/45 6C complexes were set up at 5 and 6 mg/mL, respectively. Crystals of the
Fabs were obtained in the following crystallization conditions. 85RF45.1 Fab: 0.2 M
sodium thiocyanate, pH 6.9, 20% (w/v) PEG 3350; TB31F Fab: 0.1 M HEPES, pH
7.5, 10% (v/v) 2-propanol, 20% (w/v) PEG 4000. Diffraction-quality crystals of
85RF45.1 Fab-Pfs48/45 6C and TB31F Fab-Pfs48/45 6C complexes were obtained
by microseeding in 0.1 M Bis-Tris, pH 5.5, 0.1 M ammonium acetate, 17% (w/v)
PEG 10000 and 0.1 M Bis-Tris, pH 6.0, 22% (w/v) PEG 3350, 0.2 M NaCl,
respectively. All crystals were cryo-protected by the addition of 20% (v/v) glycerol
prior to ﬂash-freezing in liquid nitrogen. Data were collected at the Canadian Light
Source 08ID-1 beamline. Data processing and scaling was performed using XDS44.
Phaser45 was used for molecular replacement using Fabs from our internal data-
base as starting models. AutoBuild46 was used to build an initial model of Pfs48/45
6C, followed by manual building in Coot47. Structure reﬁnement was carried out
with phenix.reﬁne48. Illustrations were generated using UCSF Chimera49 and The
PyMOL Molecular Graphics System, Version 2.0 Schrödinger, LLC. Software used
in this project was curated by SBGrid50. Representative electron density for the
structures is shown in Supplementary Figure 7.
Sequence polymorphism analysis. Deposited sequences for the Pfs48/45 6C
fragment were obtained from the NCBI, PlasmoDB, and Uniprot databases.
Sequence alignment was performed using Clustal Omega51.
BLI-binding studies. Binding kinetics studies for the two Fabs (85RF45.1 and
TB31F) interacting with Pfs48/45 6C were conducted using an Octet
RED96 system (Pall ForteBio). For Fab-Pfs48/45 6C binding experiments, Pfs48/45
6C monomers were loaded onto Ni-NTA biosensors followed by transfer into Fab-
containing wells. After the association steps were conducted, biosensors were then
dipped into 1× kinetics buffer (1× PBS, pH 7.4, 0.002% (v/v) Tween-20, 0.01% (w/
v) BSA) to measure dissociation. Kinetics analysis was performed using the For-
teBio data analysis software. For experiments to screen humanized variants of mAb
85RF45.1, the binding study involved immobilization of the antibodies onto anti-
human Fc (AHC) biosensors followed by dipping into the R0.6C antigen in
solution.
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Fig. 4 Pfs48/45 sequence polymorphisms in the 85RF45.1 epitope. a Weblogo58 representation of sequence variability in Pfs48/45 6C. Sequences were
compiled from the NCBI, PlasmoDB, and Uniprot databases. Invariant and polymorphic residues are colored gray and black, respectively. The buried surface
area of each Pfs48/45 residue contacted by mAb 85RF45.1 as determined by PISA59 is shown below. An asterisk denotes a Pfs48/45 residue that forms
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in orange. c Binding afﬁnity of 85RF45.1 Fab to Pfs48/45 6C constructs with point mutations representative of sequence polymorphisms in the 85RF45.1
epitope. Blue lines are representative of raw data, whereas red curves represent global ﬁtting. The different sensograms correspond to Fab concentrations
of 250, 125, 62.5, and 31.3 nM. KD’s are indicated with standard deviation and derive from at least two independent measurements
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Melting and aggregation temperatures. Melting and aggregation temperatures
for 85RF45.1 and TB31F Fabs were measured on a UNit system (Unchained Labs).
The Tm was obtained by measuring the barycentric mean ﬂuorescence, and the Tagg
was determined from static light scattering measurements at a 266 nm wavelength
during a temperature ramp from 20 to 95 °C with 1 °C increments. The equili-
bration time was set to 60 s before each measurement. The concentration of both
samples was 1.0 mg/mL. Measurements were made in 100 mM sodium acetate, pH
5.6; 100 mM HEPES, pH 7.2; and 100 mM Tris, pH 9.0; all containing 150 mM
NaCl. Measurements were made in triplicates, averaged, and standard errors were
calculated by the UNit analysis software.
SMFA. SMFA experiments were conducted as previously described52 using Ano-
pheles stephensi mosquitoes that were reared and maintained at Radboudumc, and
transgenic Pf NF54 (NF54-HGL) gametocytes that express luciferase53. Brieﬂy,
3–5-day-old mosquitoes were fed on a glass mini-feeder system containing 0.27 mL
of cultured Pf gametocytes mixed with human serum and monoclonal antibody.
For each feed, two mini-feeders containing gametocytes and human serum only
were used as a negative control. On day 9 after infection, four pools of ﬁve mos-
quitoes were collected for each condition, stored overnight at −20 °C, homogenized
by bead beating, and luciferase activity was quantiﬁed by measuring relative light
units (RLU)52. The percentage transmission reduction activity (TRA) was calcu-
lated as 100 × [1−(RLU test sample)/(RLU control group)]. The best estimate and
95% conﬁdence intervals from two separate feeds were calculated using a negative
binomial model as previously described54 without zero inﬂation.
Data availability
The crystal structures reported in this manuscript have been deposited in the Protein
Data Bank: 6E62, 6E63, 6E64, 6E65. The authors declare that all other data supporting
the ﬁndings of this study are available within the article and its Supplementary Infor-
mation ﬁles are available from the authors upon request.
Received: 4 June 2018 Accepted: 17 September 2018
References
1. Organization GWH. World malaria report 2017 (2017).
2. Sauerwein, R. W. & Bousema, T. Transmission blocking malaria vaccines:
assays and candidates in clinical development. Vaccine 33, 7476–7482 (2015).
3. Rener, J., Graves, P. M., Carter, R., Williams, J. L. & Burkot, T. R. Target
antigens of transmission-blocking immunity on gametes of Plasmodium
falciparum. J. Exp. Med. 158, 976–981 (1983).
4. Ponnudurai, T., Meuwissen, J. H., Leeuwenberg, A. D., Verhave, J. P. &
Lensen, A. H. The production of mature gametocytes of Plasmodium
falciparum in continuous cultures of different isolates infective to mosquitoes.
Trans. R. Soc. Trop. Med. Hyg. 76, 242–250 (1982).
Rat mAb 85RF45.1
Pfs48/45 6C
FW1a
b
FW1
85RF45.1–LC
1 10 20 30 40 50 60 70 80 90 100 110
1 10 20 30 40 50 60 70 80 90 100 110 120
85RF45.1–HC
TB31F–LC
TB31F–HC
FW2
FW2
CDR1
CDR1
CDR2
CDR2
CDR3
FW3
FW3
FW4
CDR3
FW4
VL VH VL VH
VL
LCDR2
LCDR1
HCDR3
LCDR3
HCDR1
HCDR2
VH
Humanized mAb TB31F
85RF45.1
Pfs48/45
6C (nM)
Tm (°C)
Tagg (°C)
SMFA IC80(μg/mL)
3.2 ± 3.1 3.7 ± 2.9
63.1 ± 0.9 74.8 ± 0.3
73.0 ± 3.063.8 ± 1.2
~1.0 – 2.0 ~0.5 – 1.0
TB31FHC FW3
LC FW2
LC FW1+3
10 –10
kcal/(mol*e)
c
e
d
Fig. 5 Humanization of transmission-blocking mAb 85RF45.1. a Sequence alignment between rat-derived mAb 85RF45.1 and its humanized counterpart
mAb TB31F. CDRs and framework regions (FW) are deﬁned according to the Kabat convention60. b Comparison of the 85RF45.1Fab-Pfs48/45 6C and the
TB31F Fab-Pfs48/45 6C crystal structures. Pfs48/45 is shown as an orange surface and secondary structure cartoon, whereas Fabs are represented as
secondary structure cartoons. Only the Fab variable region is shown for clarity. c Superposition of the variable regions of the unliganded 85RF45.1 Fab (teal
and magenta) and the unliganded TB31F Fab (green and blue) crystal structures. d Coulombic electrostatic surface coloring of the variable regions of the
unliganded 85RF45.1 Fab (left) and the unliganded TB31F Fab (right). Areas of major differences in surface electrostatics are boxed. e Biophysical and
functional parameters between 85RF45.1 and TB31F. Errors are standard deviations derived from at least three independent experiments
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-06742-9 ARTICLE
NATURE COMMUNICATIONS |          (2018) 9:4458 | DOI: 10.1038/s41467-018-06742-9 |www.nature.com/naturecommunications 7
5. Vermeulen, A. N. et al. Sequential expression of antigens on sexual stages of
Plasmodium falciparum accessible to transmission-blocking antibodies in the
mosquito. J. Exp. Med. 162, 1460–1476 (1985).
6. Nikolaeva, D., Draper, S. J. & Biswas, S. Toward the development of effective
transmission-blocking vaccines for malaria. Expert Rev. Vaccines 14, 653–680
(2015).
7. Theisen, M., Jore, M. M. & Sauerwein, R. Towards clinical development of a
Pfs48/45-based transmission blocking malaria vaccine. Expert Rev. Vaccines
16, 329–336 (2017).
8. Williamson, K. C. Pfs230: from malaria transmission-blocking vaccine
candidate toward function. Parasite Immunol. 25, 351–359 (2003).
9. Duffy, P. E. & Kaslow, D. C. A novel malaria protein, Pfs28, and Pfs25 are
genetically linked and synergistic as falciparum malaria transmission-blocking
vaccines. Infect. Immun. 65, 1109–1113 (1997).
10. Scally, S. W. et al. Molecular deﬁnition of multiple sites of antibody inhibition
of malaria transmission-blocking vaccine antigen Pfs25. Nat. Commun. 8,
1568 (2017).
11. Dinglasan, R. R. et al. Disruption of Plasmodium falciparum development by
antibodies against a conserved mosquito midgut antigen. Proc. Natl Acad. Sci.
USA 104, 13461–13466 (2007).
12. Niu, G. et al. The ﬁbrinogen-like domain of FREP1 protein is a broad-
spectrum malaria transmission-blocking vaccine antigen. J. Biol. Chem. 292,
11960–11969 (2017).
13. van Dijk, M. R. et al. A central role for P48/45 in malaria parasite male gamete
fertility. Cell 104, 153–164 (2001).
14. Roeffen, W. et al. A comparison of transmission-blocking activity with
reactivity in a Plasmodium falciparum 48/45-kD molecule-speciﬁc
competition enzyme-linked immunosorbent assay. Am. J. Trop. Med. Hyg. 52,
60–65 (1995).
15. Outchkourov, N. et al. Epitope analysis of the malaria surface antigen pfs48/45
identiﬁes a subdomain that elicits transmission blocking antibodies. J. Biol.
Chem. 282, 17148–17156 (2007).
16. Graves, P. M., Carter, R., Burkot, T. R., Quakyi, I. A. & Kumar, N. Antibodies
to Plasmodium falciparum gamete surface antigens in Papua New Guinea
sera. Parasite Immunol. 10, 209–218 (1988).
17. Ong, C. S. et al. The primary antibody response of malaria patients to
Plasmodium falciparum sexual stage antigens which are potential
transmission blocking vaccine candidates. Parasite Immunol. 12, 447–456
(1990).
18. Bousema, J. T. et al. Rapid onset of transmission-reducing antibodies in
javanese migrants exposed to malaria in Papua, Indonesia. Am. J. Trop. Med.
Hyg. 74, 425–431 (2006).
19. Bousema, J. T. et al. A longitudinal study of immune responses to Plasmodium
falciparum sexual stage antigens in Tanzanian adults. Parasite Immunol. 29,
309–317 (2007).
20. Stone, W. J. et al. Naturally acquired immunity to sexual stage P. falciparum
parasites. Parasitology 143, 187–198 (2016).
21. Stone, W. J. R. et al. Unravelling the immune signature of Plasmodium
falciparum transmission-reducing immunity. Nat. Commun. 9, 558
(2018).
22. Carter, R., Graves, P. M., Keister, D. B. & Quakyi, I. A. Properties of epitopes
of Pfs 48/45, a target of transmission blocking monoclonal antibodies, on
gametes of different isolates of Plasmodium falciparum. Parasite Immunol. 12,
587–603 (1990).
23. Targett, G. A., Harte, P. G., Eida, S., Rogers, N. C. & Ong, C. S. Plasmodium
falciparum sexual stage antigens: immunogenicity and cell-mediated
responses. Immunol. Lett. 25, 77–81 (1990).
24. Roeffen, W. et al. Plasmodium falciparum: production and characterization of
rat monoclonal antibodies speciﬁc for the sexual-stage Pfs48/45 antigen. Exp.
Parasitol. 97, 45–49 (2001).
25. Outchkourov, N. S. et al. Correctly folded Pfs48/45 protein of Plasmodium
falciparum elicits malaria transmission-blocking immunity in mice. Proc. Natl
Acad. Sci. USA 105, 4301–4305 (2008).
26. Roeffen, W. F. et al. Recombinant human antibodies speciﬁc for the Pfs48/45
protein of the malaria parasite Plasmodium falciparum. J. Biol. Chem. 276,
19807–19811 (2001).
27. Kocken, C. H. et al. Cloning and expression of the gene coding for the
transmission blocking target antigen Pfs48/45 of Plasmodium falciparum.
Mol. Biochem. Parasitol. 61, 59–68 (1993).
28. Chowdhury, D. R., Angov, E., Kariuki, T. & Kumar, N. A potent malaria
transmission blocking vaccine based on codon harmonized full length Pfs48/
45 expressed in Escherichia coli. PLoS ONE 4, e6352 (2009).
29. Theisen, M. et al. A multi-stage malaria vaccine candidate targeting both
transmission and asexual parasite life-cycle stages. Vaccine 32, 2623–2630
(2014).
30. Singh, S. K. et al. A Plasmodium falciparum 48/45 single epitope R0.6C
subunit protein elicits high levels of transmission blocking antibodies. Vaccine
33, 1981–1986 (2015).
31. Holm, L. & Laakso, L. M. Dali server update. Nucleic Acids Res. 44,
W351–W355 (2016).
32. Escalante, A. A. et al. Polymorphism in the gene encoding the Pfs48/45
antigen of Plasmodium falciparum. XI. Asembo Bay Cohort Project. Mol.
Biochem. Parasitol. 119, 17–22 (2002).
33. Arredondo, S. A. et al. Structure of the Plasmodium 6-cysteine s48/45 domain.
Proc. Natl Acad. Sci. USA 109, 6692–6697 (2012).
34. Arredondo, S. A. & Kappe, S. H. I. The s48/45 six-cysteine proteins: mediators
of interaction throughout the Plasmodium life cycle. Int. J. Parasitol. 47,
409–423 (2017).
35. Simon, N., Kuehn, A., Williamson, K. C. & Pradel, G. Adhesion protein
complexes of malaria gametocytes assemble following parasite transmission to
the mosquito. Parasitol. Int. 65, 27–30 (2016).
36. Swearingen, K. E. et al. Interrogating the Plasmodium sporozoite surface:
identiﬁcation of surface-exposed proteins and demonstration of glycosylation
on CSP and TRAP by mass spectrometry-based proteomics. PLoS Pathog. 12,
e1005606 (2016).
37. Cova, M., Rodrigues, J. A., Smith, T. K. & Izquierdo, L. Sugar activation and
glycosylation in Plasmodium. Malar. J. 14, 427 (2015).
38. Lopaticki, S. et al. Protein O-fucosylation in Plasmodium falciparum ensures
efﬁcient infection of mosquito and vertebrate hosts. Nat. Commun. 8, 561
(2017).
39. Kimura, E. A., Couto, A. S., Peres, V. J., Casal, O. L. & Katzin, A. M. N-linked
glycoproteins are related to schizogony of the intraerythrocytic stage in
Plasmodium falciparum. J. Biol. Chem. 271, 14452–14461 (1996).
40. Choi, Y., Hua, C., Sentman, C. L., Ackerman, M. E. & Bailey-Kellogg, C.
Antibody humanization by structure-based computational protein design.
MAbs 7, 1045–1057 (2015).
41. Choi, Y., Ndong, C., Griswold, K. E. & Bailey-Kellogg, C. Computationally
driven antibody engineering enables simultaneous humanization and
thermostabilization. Protein Eng. Des. Sel. 29, 419–426 (2016).
42. Gao, S. H., Huang, K., Tu, H. & Adler, A. S. Monoclonal antibody humanness
score and its applications. BMC Biotechnol. 13, 55 (2013).
43. Aricescu, A. R., Lu, W. & Jones, E. Y. A time- and cost-efﬁcient system for
high-level protein production in mammalian cells. Acta Crystallogr. D Biol.
Crystallogr. 62, 1243–1250 (2006).
44. Kabsch, W. Xds. Acta Crystallogr. D Biol. Crystallogr. 66, 125–132 (2010).
45. McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40,
658–674 (2007).
46. Terwilliger, T. C. et al. Iterative model building, structure reﬁnement and
density modiﬁcation with the PHENIX AutoBuild wizard. Acta Crystallogr. D
Biol. Crystallogr. 64, 61–69 (2008).
47. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development
of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486–501 (2010).
48. Adams, P. D. et al. PHENIX: a comprehensive Python-based system for
macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66,
213–221 (2010).
49. Pettersen, E. F. et al. UCSF Chimera—a visualization system for exploratory
research and analysis. J. Comput. Chem. 25, 1605–1612 (2004).
50. Morin, A. et al. Collaboration gets the most out of software. eLife 2, e01456
(2013).
51. Sievers, F. et al. Fast, scalable generation of high-quality protein multiple
sequence alignments using Clustal Omega. Mol. Syst. Biol. 7, 539 (2011).
52. Stone, W. J. et al. A scalable assessment of Plasmodium falciparum
transmission in the standard membrane-feeding assay, using transgenic
parasites expressing green ﬂuorescent protein-luciferase. J. Infect. Dis. 210,
1456–1463 (2014).
53. Vos, M. W. et al. A semi-automated luminescence based standard membrane
feeding assay identiﬁes novel small molecules that inhibit transmission of
malaria parasites by mosquitoes. Sci. Rep. 5, 18704 (2015).
54. Miura, K. et al. Qualiﬁcation of standard membrane-feeding assay with
Plasmodium falciparum malaria and potential improvements for future
assays. PLoS ONE 8, e57909 (2013).
55. Tonkin, M. L. et al. Structural and biochemical characterization of
Plasmodium falciparum 12 (Pf12) reveals a unique interdomain organization
and the potential for an antiparallel arrangement with Pf41. J. Biol. Chem. 288,
12805–12817 (2013).
56. Parker, M. L., Peng, F. & Boulanger, M. J. The structure of Plasmodium
falciparum blood-stage 6-Cys protein Pf41 reveals an unexpected intra-
domain insertion required for Pf12 coordination. PLoS ONE 10, e0139407
(2015).
57. Crawford, J. et al. Structural and functional characterization of SporoSAG: a
SAG2-related surface antigen from Toxoplasma gondii. J. Biol. Chem. 285,
12063–12070 (2010).
58. Crooks, G. E., Hon, G., Chandonia, J. M. & Brenner, S. E. WebLogo: a
sequence logo generator. Genome Res. 14, 1188–1190 (2004).
59. Krissinel, E. & Henrick, K. Inference of macromolecular assemblies from
crystalline state. J. Mol. Biol. 372, 774–797 (2007).
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-06742-9
8 NATURE COMMUNICATIONS |          (2018) 9:4458 | DOI: 10.1038/s41467-018-06742-9 | www.nature.com/naturecommunications
60. Kabat, E. A. W. T., Foeller, C., Perry, H. M. & Gottesman K. S. Sequences of
Proteins of Immunological Interest (DIANE Publishing, Darby, PA, 1992).
Acknowledgements
We thank M. Theisen for providing us with the R0.6C reagent for screening humanized
mAbs. The excellent work by Marga van de Vegte-Bolmer, Rianne Stoter, Wouter
Graumans, and Geert-Jan van Gemert for conducting Standard Membrane Feeding
Assays is highly appreciated. We thank Shwu-Maan Lee, Emily Locke, and Christian
Ockenhouse for assistance in designing experiments and for the analysis of data relating
to the selection of mAb TB31F. We thank Ashley Birkett and Jeffery Smith for helpful
comments on the manuscript. This work was funded by PATH’s Malaria Vaccine
Initiative under grant OPP1108403 from the Bill & Melinda Gates Foundation. The
production of mAb TB31F was supported in part by the Intramural Research Program of
the NIAID, NIH. X-ray diffraction experiments were performed using beamline 08ID-1
at the Canadian Light Source, which is supported by the Canada Foundation for
Innovation, Natural Sciences and Engineering Research Council of Canada, the Uni-
versity of Saskatchewan, the Government of Saskatchewan, Western Economic Diver-
siﬁcation Canada, the National Research Council Canada, and the Canadian Institutes of
Health Research. This research was undertaken, in part, thanks to funding from the
Canada Research Chairs program (to J.-P.J.).
Author Contributions
Experimental conception and design: C.R.K. and J.-P.J.; data acquisition: P.K., A.S., M.M.
J., and K.M.; analysis of data: P.K., A.S., M.M.J., K.M., R.W.S., C.R.K., and J.-P.J.; design
of humanized mAb TB31F: A.L. and J.L.; design of selection criteria and identiﬁcation of
TB31F as the lead: M.J.M., V.L.P., C.R.K., and R.W.S.; drafting the article or revising it
critically for important intellectual content: P.K., A.S., M.M.J., R.W.S., C.R.K., and J.-P.J.
Additional information
Supplementary Information accompanies this paper at https://doi.org/10.1038/s41467-
018-06742-9.
Competing interests: The authors declare no competing interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional afﬁliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2018
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-06742-9 ARTICLE
NATURE COMMUNICATIONS |          (2018) 9:4458 | DOI: 10.1038/s41467-018-06742-9 |www.nature.com/naturecommunications 9
